Ruxolitinib as an Effective and Steroid-Sparing First-Line Treatment in Newly Diagnosed BOS Patients After Hematopoietic Stem Cell Transplantation

Overview of attention for article published in Frontiers in Pharmacology, July 2022

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 2 Dimensions

Readers on

mendeley: 5 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 5,881 followers.

New Research: Ruxolitinib as an Effective and Steroid-Sparing First-Line Treatment in Newly Diagnosed BOS Patients After Hematopoietic Stem Cell Transplantation https://t.co/rf0Wsubkqq #pharmacology

06 Jul 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.